Macnica enters into capital and business alliance with Kokoro Mill to develop and sell wearable electrocardiographs - Enters the medical field by obtaining permission to sell and lend highly controlled medical devices -

Macnica, Ltd. (Headquarters: Yokohama City, Kanagawa Prefecture, President CEO: Kazumasa Kazumasa Hara, hereinafter referred to as Macnica) is collaborating with Kokoro Mill Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Representative Board Director: Daiki Hayashi, hereinafter referred to as Kokoro Mill Co., Ltd.) to develop next-generation equipment. We are pleased to announce today that we have entered into a capital and business alliance for the purpose of jointly developing service solutions and selling current products. In addition, in order to strengthen our digital medical business and provide medical-level services, Macnica has obtained permission to sell and lend highly controlled medical equipment, etc. We have recently received a license to sell and lend highly controlled medical equipment, etc., and we have recently received a license to sell and lend highly controlled medical equipment, etc. Wearable electrocardiograms from Kokoro Mill, which have received high praise in the medical field. We will start selling measurement and analysis services.

Background of Business Alliance with KokoroMill, Inc.
In support of KokoroMill's vision of avoiding unexpected cardiac events and visualizing potential health risks in both medical and non-medical healthcare, Macnica has formed this capital and business alliance with the expectation that the complementary capabilities of the two companies will further accelerate the resolution of social issues related to healthcare. The two companies have agreed on this capital and business alliance.

■Social background and services that require wearable electrocardiographs
The number of patients with heart disease in Japan is extremely large, and the number of patients is increasing every year. According to the Ministry of Health, Labor and Welfare's announcement ^* in 2021, the number of deaths due to heart disease is approximately 210,000 annually, accounting for approximately 15% of all deaths, and malignant neoplasms (cancer) are the most common cause of death among Japanese people. It is the second most common cause of death at approximately 27%. Furthermore, many people have risk factors for heart disease, including high blood pressure, and heart disease has become a major health problem in Japan.
Kokoro Mill provides electrocardiogram analysis services using "single-use" wearable Holter electrocardiographs for medical institutions. Since its launch in 2023, it has been used in more than 50 facilities nationwide, including medical institutions that treat a large number of arrhythmia cases. In addition to providing the device itself, Cocoro Mill's clinical laboratory technicians and cardiologists analyze the acquired electrocardiograms and return the reports, contributing to reducing the burden of interpretation work at medical institutions.

[Advantages of single-use Holter electrocardiograph (NASA guided type)]
・Can be worn continuously for up to 7 days, increasing the probability of detecting arrhythmia
・By having inventory at the site, testing can be performed even at the first visit, reducing the burden on patients when visiting the hospital.
・Since it is a “one-time use” device, there is no need to manage the lending and return of equipment.
・Since Kokoro Mill analyzes electrocardiogram waveforms, analysis work for laboratory technicians at medical institutions can be reduced.

■ Macnica 's future initiatives
Going forward, Macnica will contribute to the early detection of heart disease such as arrhythmia by popularizing the wearable electrocardiograph provided by Cocoro Mill. In addition, we are proceeding with the development of service solutions for next-generation devices with Kokoro Mill, and with a view to expanding overseas in the future, we are developing sales and clinical evidence for medical institutions in Japan, and BtoB business for general companies and medical examination providers. We will continue to focus on this.

■ Macnica 's healthcare initiatives
In response to social issues such as reducing social security costs, extending healthy life expectancy, and building a society where people can work for the rest of their lives due to a super-aging society, Macnica is working on a healthcare business that utilizes cutting-edge technology and data. In addition to preventive services and nursing care monitoring services, we are focusing on the prevention of mental health and chronic diseases (lifestyle-related diseases). Additionally, in addition to obtaining licenses for the Type 2 Medical Device Manufacturing and Sales Business and Medical Device Manufacturing Business in January 2022, we have recently acquired a new license for sales and rental of highly controlled medical devices, etc., allowing us to sell medical devices. This will enable us to make a full-scale entry into the medical field.